Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis

Overview

Journal Vaccines (Basel)

Date 2021 Apr 3

PMID 33799544

Citations 6

Authors

Chathika Krishan Weerasuriya

Rebecca Claire Harris

Matthew Quaife

Christopher Finn McQuaid

Richard G White

Gabriela B Gomez

Affiliations

Soon will be listed here.

Abstract

New tuberculosis vaccines have made substantial progress in the development pipeline. Previous modelling suggests that adolescent/adult mass vaccination may cost-effectively contribute towards achieving global tuberculosis control goals. These analyses have not considered the budgetary feasibility of vaccine programmes. We estimate the maximum total cost that the public health sectors in India and China should expect to pay to introduce a M72/AS01-like vaccine deemed cost-effective at country-specific willingness to pay thresholds for cost-effectiveness. To estimate the total disability adjusted life years (DALYs) averted by the vaccination programme, we simulated a 50% efficacy vaccine providing 10-years of protection in post-infection populations between 2027 and 2050 in India and China using a dynamic transmission model of . We investigated two mass vaccination strategies, both delivered every 10-years achieving 70% coverage: Vaccinating adults and adolescents (age ≥10y), or only the most efficient 10-year age subgroup (defined as greatest DALYs averted per vaccine given). We used country-specific thresholds for cost-effectiveness to estimate the maximum total cost (C) a government should be willing to pay for each vaccination strategy. Adult/adolescent vaccination resulted in a C of $21 billion (uncertainty interval [UI]: 16-27) in India, and $15B (UI:12-29) in China at willingness to pay thresholds of $264/DALY averted and $3650/DALY averted, respectively. Vaccinating the highest efficiency age group (India: 50-59y; China: 60-69y) resulted in a C of $5B (UI:4-6) in India and $6B (UI:4-7) in China. Mass vaccination against tuberculosis of all adults and adolescents, deemed cost-effective, will likely impose a substantial budgetary burden. Targeted tuberculosis vaccination, deemed cost-effective, may represent a more affordable approach.

Citing Articles

Adult vaccination in India: A rapid review of current status & implementation challenges.

Bhattacharyya A, Shahabuddin S Indian J Med Res. 2024; 160(3&4):279-292.

PMID: 39632644 PMC: 11619099. DOI: 10.25259/IJMR_1521_2024.

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review.

Buis J, Jerene D, Gebhard A, Bakker R, Majidulla A, Kerkhoff A PLOS Glob Public Health. 2024; 4(8):e0002885.

PMID: 39172796 PMC: 11340902. DOI: 10.1371/journal.pgph.0002885.

Updating age-specific contact structures to match evolving demography in a dynamic mathematical model of tuberculosis vaccination.

Weerasuriya C, Harris R, McQuaid C, Gomez G, White R PLoS Comput Biol. 2022; 18(4):e1010002.

PMID: 35452459 PMC: 9067655. DOI: 10.1371/journal.pcbi.1010002.

It Takes a Village: The Multifaceted Immune Response to Infection and Vaccine-Induced Immunity.

Larsen S, Williams B, Rais M, Coler R, Baldwin S Front Immunol. 2022; 13:840225.

PMID: 35359957 PMC: 8960931. DOI: 10.3389/fimmu.2022.840225.

Accelerating research and development of new vaccines against tuberculosis: a global roadmap.

Cobelens F, Suri R, Helinski M, Makanga M, Weinberg A, Schaffmeister B Lancet Infect Dis. 2022; 22(4):e108-e120.

PMID: 35240041 PMC: 8884775. DOI: 10.1016/S1473-3099(21)00810-0.

References

Ochalek J, Lomas J, Claxton K . Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health. 2018; 3(6):e000964. PMC: 6231096. DOI: 10.1136/bmjgh-2018-000964. View

Harris R, Sumner T, Knight G, Zhang H, White R . Potential impact of tuberculosis vaccines in China, South Africa, and India. Sci Transl Med. 2020; 12(564). DOI: 10.1126/scitranslmed.aax4607. View

Bilinski A, Neumann P, Cohen J, Thorat T, McDaniel K, Salomon J . When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLoS Med. 2017; 14(10):e1002397. PMC: 5624570. DOI: 10.1371/journal.pmed.1002397. View

Langley I, Lin H, Squire S . Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa. Lancet Glob Health. 2015; 3(2):e83-4. DOI: 10.1016/S2214-109X(14)70370-5. View

Tait D, Hatherill M, Van Der Meeren O, Ginsberg A, van Brakel E, Salaun B . Final Analysis of a Trial of M72/AS01 Vaccine to Prevent Tuberculosis. N Engl J Med. 2019; 381(25):2429-2439. DOI: 10.1056/NEJMoa1909953. View

Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K . Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med. 2016; 13(5):e1002032. PMC: 4886962. DOI: 10.1371/journal.pmed.1002032. View

Harris R, Sumner T, Knight G, Evans T, Cardenas V, Chen C . Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. Lancet Glob Health. 2019; 7(2):e209-e218. DOI: 10.1016/S2214-109X(18)30452-2. View

Wang L, Zhang H, Ruan Y, Chin D, Xia Y, Cheng S . Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet. 2014; 383(9934):2057-2064. DOI: 10.1016/S0140-6736(13)62639-2. View

Paulden M, OMahony J, McCabe C . Determinants of Change in the Cost-effectiveness Threshold. Med Decis Making. 2016; 37(2):264-276. DOI: 10.1177/0272989X16662242. View

10.

Aggarwal R, Chen Q, Goel A, Seguy N, Pendse R, Ayer T . Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS One. 2017; 12(5):e0176503. PMC: 5435174. DOI: 10.1371/journal.pone.0176503. View

11.

Knight G, Griffiths U, Sumner T, Laurence Y, Gheorghe A, Vassall A . Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014; 111(43):15520-5. PMC: 4217399. DOI: 10.1073/pnas.1404386111. View

12.

Bertram M, Lauer J, de Joncheere K, Edejer T, Hutubessy R, Kieny M . Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016; 94(12):925-930. PMC: 5153921. DOI: 10.2471/BLT.15.164418. View

13.

Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias H . WHO's new end TB strategy. Lancet. 2015; 385(9979):1799-1801. DOI: 10.1016/S0140-6736(15)60570-0. View

14.

Salomon J, Haagsma J, Davis A, Maertens de Noordhout C, Polinder S, Havelaar A . Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015; 3(11):e712-23. DOI: 10.1016/S2214-109X(15)00069-8. View

15.

Wu S, Yang P, Li H, Ma C, Zhang Y, Wang Q . Influenza vaccination coverage rates among adults before and after the 2009 influenza pandemic and the reasons for non-vaccination in Beijing, China: a cross-sectional study. BMC Public Health. 2013; 13:636. PMC: 3708734. DOI: 10.1186/1471-2458-13-636. View

16.

Yu W, Lu M, Wang H, Rodewald L, Ji S, Ma C . Routine immunization services costs and financing in China, 2015. Vaccine. 2018; 36(21):3041-3047. DOI: 10.1016/j.vaccine.2018.04.008. View

17.

Crooke S, Ovsyannikova I, Poland G, Kennedy R . Immunosenescence and human vaccine immune responses. Immun Ageing. 2019; 16:25. PMC: 6743147. DOI: 10.1186/s12979-019-0164-9. View

18.

Chatterjee S, Das P, Nigam A, Nandi A, Brenzel L, Ray A . Variation in cost and performance of routine immunisation service delivery in India. BMJ Glob Health. 2018; 3(3):e000794. PMC: 6014207. DOI: 10.1136/bmjgh-2018-000794. View

19.

Weerasuriya C, Clark R, White R, Harris R . New tuberculosis vaccines: advances in clinical development and modelling. J Intern Med. 2020; 288(6):661-681. DOI: 10.1111/joim.13197. View

20.

Zheng Y, Yang P, Wu S, Ma C, Seale H, MacIntyre C . A cross-sectional study of factors associated with uptake of vaccination against influenza among older residents in the postpandemic season in Beijing, China. BMJ Open. 2013; 3(11):e003662. PMC: 3840337. DOI: 10.1136/bmjopen-2013-003662. View